Logo

Alnylam Licenses RNAi Patent to RNAx

Jan 27, 2004

NEW YORK, Jan. 27 (GenomeWeb News) - Alnylam Pharmaceuticals, through its German affiliate, Ribopharma, has granted a license to its RNAi patent to Ribopharma, the company said today.

 

The patent covers the use of short double-stranded RNAs for RNA interference. RNAx, based in Berlin, will pay an initial and annual licensing fees, as well as royalties on services it provides using the technology.

 

Earlier this month, Alnylam, based in Cambridge, Mass., licensed the patent to Invitrogen, Cell Signaling Technology, and Cenix Bioscience.

 

Breaking News
The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.